Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 26, Issue 4, 2011, Pages 767-778

  Akhter, Hasina ^a   Katre, Ashwini ^a   Li, Ling ^b   Liu, Xuebo ^c   Liu, Rui Ming ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NORTHWEST A F UNIVERSITY   (China)

Author keywords

Alzheimer's disease; amyloid degradation; amyloid efflux; antioxidant

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLUTATHIONE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TERT BUTYLHYDROQUINONE; UROKINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DIETARY INTAKE; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL MODEL; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; TRANSGENIC MOUSE;

EID: 80055056469     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110512     Document Type: Article

References (64)

1. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Abeta] peptide vaccination prevents memory loss in an animal model of Alzheimers disease. Nature 408, 982-985. (Pubitemid 32101645)
2. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJF, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta]-Amyloid slow cognitive decline in Alzheimers disease. Neuron 38, 547-554. (Pubitemid 36645030)
3. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
4. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates A pathology and behavioral deficits in a mouse model of Alzheimers disease. J Neurosci 30, 11157-11166.
5. Kimura R, Devi L, Ohno M (2010) Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimers disease transgenic mice. J Neurochem 113, 248-261.
6. Fu AL, Dong ZH, Sun MJ (2006) Protective effect of Nacetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res 1109, 201-206.
7. Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT (2005) Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimers APP 5′ untranslated region. Curr Alzheimer Res 2, 249-254. (Pubitemid 40862888)
8. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW, Jr (2007) Chronic dietary alphalipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28, 213-225. (Pubitemid 44894634)
9. Hager K, Kenklies M, McAfoose J, Engel J, Munch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimers disease-a 48 months follow-up analysis. J Neural Transm Suppl 189-193.
10. Alamed J, Chaiyasit W, McClements DJ, Decker EA (2009) Relationships between free radical scavenging and antioxidant activity in foods. J Agric Food Chem 57, 2969-2976.
11. Liu RM, Shi MM, Giulivi C, Forman HJ (1998) Quinones increase gamma-glutamyl transpeptidase expression by multiple mechanisms in rat lung epithelial cells. Am J Physiol 274, L330-L336.
12. Liu RM, Hu H, Robison TW, Forman HJ (1996) Differential enhancement of gamma-glutamyl transpeptidase and gammaglutamylcysteine synthetase by tert-butylhydroquinone in rat lung epithelial L2 cells. Am J Respir Cell Mol Biol 14, 186-191. (Pubitemid 126441392)
13. Liu RM, Hu H, Robison TW, Forman HJ (1996) Increased gamma- glutamylcysteine synthetase and gamma-glutamyl transpeptidase activities enhance resistance of rat lung epithelial L2 cells to quinone toxicity. Am J Respir Cell Mol Biol 14, 192-197. (Pubitemid 126441393)
14. Li J, Johnson D, Calkins M, Wright L, Svendsen C, Johnson J (2005) Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83, 313-328. (Pubitemid 40227901)
15. Shih AY, Li P, Murphy TH (2005) Asmall-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25, 10321-10335. (Pubitemid 41636229)
16. Duvoix A, Schnekenburger M, Delhalle S, Blasius R, Borde-Chiché P, Morceau F, Dicato M, Diederich M (2004) Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett 216, 207-219. (Pubitemid 39463325)
17. Prince M, Li Y, Childers A, Itoh K, Yamamoto M, Kleiner HE (2009) Comparison of citrus coumarins on carcinogendetoxifying enzymes in Nrf2 knockout mice. Toxicol Lett 185, 180-186.
18. Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24, 1101-1112. (Pubitemid 38177017)
19. Abdel-Wahab MH (2005) Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2′- methylphenyl)-1,2,3,6-tetrahydropyridine (2′-methyl-MPTP) in mice. J Biochem Mol Toxicol 19, 32-41. (Pubitemid 40315389)
20. Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P, Murphy TH (2005) Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 280, 22925-22936. (Pubitemid 40853201)
21. Shah ZA, Li RC, Thimmulappa RK, Kensler TW, Yamamoto M, Biswal S, Dore S (2007) Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience 147, 53-59. (Pubitemid 46881103)
22. Liu XY, Li CY, Bu H, Li Z, Li B, Sun MM, Guo YS, Zhang L, Ren WB, Fan ZL, Wu DX, Wu SY (2008) The neuroprotective potential of phase II enzyme inducer on motor neuron survival in traumatic spinal cord injury in vitro. Cell Mol Neurobiol 28, 769-779. (Pubitemid 351905070)
23. Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 87, 1659-1669.
24. Liu RM, van Groen T, Katre A, Cao D, Kadisha I, Ballinger C, Wang L, Carroll SL, Li L (2011) Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimers disease. Neurobiol Aging 32, 1079-1089.
25. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimers amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499. (Pubitemid 32038587)
26. Vayalil PK, Olman M, Murphy-Ullrich JE, Postlethwait EM, Liu RM (2005) Glutathione restores collagen degradation in TGF-beta-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. Am J Physiol Lung Cell Mol Physiol 289, L937-L945. (Pubitemid 41681328)
27. Beutler E (1969) Effect of flavin compounds on glutathione reductase activity: In vivo and in vitro studies. J Clin Invest 48, 1957-1966.
28. Van Nostrand WE, Porter M (1999) Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38, 11570-11576.
29. Periz G, Fortini ME (2000) Proteolysis in Alzheimers disease. Can plasmin tip the balance? EMBO Rep 1, 477-478.
30. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimers disease brains. EMBO Rep 1, 530-535.
31. Melchor JP, Pawlak R, Strickland S (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 23, 8867-8871. (Pubitemid 37210899)
32. Exley C, Korchazhkina OV (2001) Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures. Neuroreport 12, 2967-2970. (Pubitemid 32882017)
33. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimers disease. CNS Neurol Disord Drug Targets 8, 16-30.
34. Zlokovic BV (2008) New therapeutic targets in the neurovascular pathway in Alzheimers disease. Neurotherapeutics 5, 409-414. (Pubitemid 351952489)
35. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimers amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27, 909-918. (Pubitemid 46659038)
36. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimers amyloid-beta peptide: Implications for therapeutic design and diagnostic tests. Mol Psychiatry 14, 469-486.
37. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid betaprotein clearance and Alzheimers disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106, 1159-1166.
38. Aderinwale OG, Ernst HW, Mousa SA (2010) Current therapies and new strategies for the management of Alzheimers disease. Am J Alzheimers Dis Other Demen 25, 414-424.
39. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20, 3937-3946. (Pubitemid 30365663)
40. Melchor JP, Pawlak R, Chen Z, Strickland S (2003) The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimers disease. J Mol Neurosci 20, 287-289. (Pubitemid 38146984)
41. Turner AJ, Nalivaeva NN (2007) New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Int Rev Neurobiol 82, 113-135.
42. Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, VaughanDE(2007) Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 5, 1500-1508. (Pubitemid 46965381)
43. Vaughan DE, De Taeye BM, Eren M (2007) PAI-1 antagonists: Predictable indications and unconventional applications. Curr Drug Targets 8, 962-970. (Pubitemid 47578144)
44. CacquevelM, Launay S, Castel H, Benchenane K, Cheenne S, Buee L, Moons L, Delacourte A, Carmeliet P, Vivien D (2007) Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 27, 164-173. (Pubitemid 47096796)
45. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN (2008) Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105, 8754-8759. (Pubitemid 351987752)
46. Vayalil PK, Iles KE, Choi J, Yi A-K, Postlethwait EM, Liu R-M (2007) Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol 293, L1281-L1292. (Pubitemid 350159412)
47. Liu RM, Choi J, Wu JH, Gaston Pravia KA, Lewis KM, Brand JD, Mochel NS, Krzywanski DM, Lambeth JD, Hagood JS, Forman HJ, Thannickal VJ, Postlethwait EM (2010) Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J Biol Chem 285, 16239-16247.
48. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB (2003) Reactive oxygen species mediate TGFbeta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 309, 961-966. (Pubitemid 37122623)
49. Uchida Y, Ohba K, Yoshioka T, Irie K, Muraki T, Maru Y (2004) Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. J Biol Chem 279, 4075-4083. (Pubitemid 38198991)
50. Hong HK, SongCY, Kim BC, LeeHS(2006)ERKcontributes to the effects of Smad signaling on oxidized LDL-induced PAI-1 expression in human mesangial cells. Transl Res 148, 171-179. (Pubitemid 44416362)
51. Vulin AI, Stanley FM (2004) Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 279, 25172-25178. (Pubitemid 38756767)
52. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemiainduced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97, 12222-12226.
53. Liu R-M, Liu Y, Forman HJ, Olman M, Tarpey MM (2004) Glutathione regulates transforming growth factorbeta-stimulated collagen production in fibroblasts. Am J Physiol Lung Cell Mol Physiol 286, L121-L128. (Pubitemid 38055866)
54. Liu R-M, Choi J (2000) Age-associated decline of gammaglutamylcysteine synthetase gene expression in rats. Free Radic Biol Med 28, 566-574. (Pubitemid 30136038)
55. Liu RM (2002) Down-Regulation of gamma-Glutamylcysteine Synthetase Regulatory Subunit Gene Expression in Rat Brain Tissue During Aging. J Neurosci Res 68, 344-351.
56. Liu RM, Dickinson DA (2003) Decreased synthetic capacity underlies the age-associated decline in glutathione content in Fisher 344 rats. Antioxid Redox Signal 5, 529-536. (Pubitemid 37315139)
57. Liu H, Wang H, Shenvi S, Hagen TM, Liu R-M (2004) Glutathione Metabolism during Aging and in Alzheimer Disease. Ann NY Acad Sci 1019, 346-349. (Pubitemid 38951332)
58. Liu H, Harrell LE, Shenvi S, Hagen T, LiuRM(2005) Gender differences in glutathione metabolism in Alzheimers disease. J Neurosci Res 79, 861-867. (Pubitemid 40476510)
59. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloidbeta protein in Alzheimers disease. Acta Neuropathol 112, 405-415.
60. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
61. Sultana R, BanksWA, ButterfieldDA(2010) Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimers disease. J Neurosci Res 88, 469-477.
62. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, Ghiso J, Frangione B, Zlokovic BV (2002) Brain clearance of Alzheimers amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 10, 359-368. (Pubitemid 34746318)
63. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimers disease: LRP-antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17, 553-570.
64. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu G, BanksWA, Butterfield DA (2010) Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Abeta accumulation in AD brain. Free Radic Biol Med 49, 1798-1803.